- The report assesses Lipodystrophy therapeutics based on drug target , mechanism of action ( MoA ), route of administration ( RoA ) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Lipodystrophy
Reasons To Buy - Gain strategically significant competitor information , analysis , and insights to formulate effective R & D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Lipodystrophy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it ' s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Buy a Sample copy of This Report @ http :// www . radiantinsights . com / research / lipodystrophy-pipeline-reviewh2-2016 / request-sample
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lipodystrophy Overview 6 Therapeutics Development 7 Pipeline Products for Lipodystrophy - Overview 7 Lipodystrophy - Therapeutics under Development by Companies 8 Lipodystrophy - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Lipodystrophy - Products under Development by Companies 11 Lipodystrophy - Companies Involved in Therapeutics Development 12 Aegerion Pharmaceuticals , Inc . 12 Akcea Therapeutics Inc 13 Ambrx , Inc . 14 Amunix Operating Inc . 15 Bolder Biotechnology , Inc . 16 Lipodystrophy - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 AMX-342 - Drug Profile 25 Product Description 25 Mechanism Of Action 25